Nancy E Davidson

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Ting Bao
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Breast Cancer Res 9:115. 2007
  2. ncbi request reprint The maturation of medical oncology
    Nancy E Davidson
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet Oncol 8:457-8. 2007
  3. ncbi request reprint Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
    J Clin Oncol 23:5973-82. 2005
  4. ncbi request reprint What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
    Tatiana M Prowell
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, Maryland 21231 1000, USA
    Oncologist 9:507-17. 2004
  5. ncbi request reprint Ongoing US cooperative group trials using taxanes in the adjuvant setting
    Nancy E Davidson
    Johns Hopkins Oncology Center, Baltimore, MD 21231 1000, USA
    Clin Breast Cancer 3:S53-8. 2002
  6. ncbi request reprint Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines
    Allison Pledgie
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Biol Chem 280:39843-51. 2005
  7. ncbi request reprint Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells
    Yi Huang
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD and SLIL Biomedical Corp, Madison, WI, USA
    Mol Cancer Res 2:81-8. 2004
  8. pmc Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells
    Yi Huang
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    J Biol Chem 281:19055-63. 2006
  9. pmc Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 1M52, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 139:135-43. 2013
  10. pmc Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells
    Qun Zhou
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB Room 144, Baltimore, MD 21231, USA
    Mol Cancer Res 6:873-83. 2008

Research Grants

  1. DNA METHYLATION AS A DETERMINANT OF BREAST CANCER
    Nancy Davidson; Fiscal Year: 2002
  2. SPORE IN BREAST CANCER
    Nancy Davidson; Fiscal Year: 2007

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. pmc Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Ting Bao
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Breast Cancer Res 9:115. 2007
    ....
  2. ncbi request reprint The maturation of medical oncology
    Nancy E Davidson
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet Oncol 8:457-8. 2007
  3. ncbi request reprint Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
    J Clin Oncol 23:5973-82. 2005
    ..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established...
  4. ncbi request reprint What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
    Tatiana M Prowell
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, Maryland 21231 1000, USA
    Oncologist 9:507-17. 2004
    ....
  5. ncbi request reprint Ongoing US cooperative group trials using taxanes in the adjuvant setting
    Nancy E Davidson
    Johns Hopkins Oncology Center, Baltimore, MD 21231 1000, USA
    Clin Breast Cancer 3:S53-8. 2002
    ..Ongoing trials will help to further define the role of taxanes in the adjuvant setting for patients with operable breast cancer...
  6. ncbi request reprint Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines
    Allison Pledgie
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Biol Chem 280:39843-51. 2005
    ..These data suggested that SSAT and SMO(PAOh1) activities are the major mediators of the cellular response of breast tumor cells to BENSpm and that PAO plays little or no role in this response...
  7. ncbi request reprint Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells
    Yi Huang
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD and SLIL Biomedical Corp, Madison, WI, USA
    Mol Cancer Res 2:81-8. 2004
    ....
  8. pmc Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells
    Yi Huang
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    J Biol Chem 281:19055-63. 2006
    ..Taken together, these results suggest a novel antiestrogenic mechanism for specific polyamine analogues in human breast cancer cells...
  9. pmc Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 1M52, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 139:135-43. 2013
    ..BSA was not the main source of pharmacokinetic variability. Fixed-dose capecitabine is feasible, and simplifies dosing...
  10. pmc Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells
    Qun Zhou
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB Room 144, Baltimore, MD 21231, USA
    Mol Cancer Res 6:873-83. 2008
    ..Our studies suggest a new role for HDAC1 and identify a novel mechanism of action for the HDAC inhibitors as down-regulators of DNMT1...
  11. pmc Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells
    Madhavi Billam
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, USA
    Breast Cancer Res Treat 120:581-92. 2010
    ..These findings suggest that zebularine is an effective DNMT inhibitor and demethylating agent in human breast cancer cell lines and potentiates the effects of other epigenetic therapeutics like decitabine and vorinostat...
  12. ncbi request reprint PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
    Ben Ho Park
    Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Cell 12:297-9. 2007
    ..This study extends important work of others and forms the rationale for future investigations combining inhibitors of the PI3 kinase pathway in conjunction with trastuzumab therapy...
  13. pmc Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles
    Abena S Agyeman
    Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Breast Cancer Res Treat 132:175-87. 2012
    ..Collectively, these studies served to identify potential biomarkers that can be used in clinical trials to investigate the initial pharmacodynamic action of SFN in the breast...
  14. ncbi request reprint Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells
    Judith C Keen
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 3:1304-12. 2004
    ..These gene products may be novel targets to be further explored in the development of new therapeutics for ER negative breast cancer...
  15. pmc Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer
    Michael A Jacobs
    The Russell H Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Acad Radiol 17:1477-85. 2010
    ..The aim of this prospective study was to investigate using multiparametric and multinuclear magnetic resonance imaging during preoperative systemic therapy for locally advanced breast cancer...
  16. ncbi request reprint Epigenetic regulation as a new target for breast cancer therapy
    Vered Stearns
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Invest 25:659-65. 2007
  17. doi request reprint Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells
    Qun Zhou
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRBI Room 144, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 117:443-51. 2009
    ..Thus, SAHA may not only reactivate silenced ER, but also simultaneously deplete EGFR expression. These data suggest that inhibition of HDAC is a promising epigenetic therapy for ER-negative human breast cancer...
  18. pmc Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer
    Yuan Yao
    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Breast Cancer Res Treat 124:585-91. 2010
    ..Moreover, shikonin reverses the inhibitory effects of estrogen on this pathway and may contribute to breast cancer prevention...
  19. ncbi request reprint Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells
    Dipali Sharma
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, MD 21231, USA
    Mol Endocrinol 19:1740-51. 2005
    ..These findings will aid in the application of agents targeting epigenetic changes in the treatment of breast cancer...
  20. pmc Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer
    Vered Stearns
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 19:4008-16. 2013
    ..We evaluated biomarker modulation in breast cancer tissues obtained from women with newly diagnosed invasive disease who received vorinostat and those who did not...
  21. pmc Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells
    Qingsong Zhu
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    Breast Cancer Res Treat 136:57-66. 2012
    ..Taken together, these data provide insight into a novel antiestrogenic mechanism for polyamine biosynthesis enzymes in breast cancer...
  22. pmc A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
    Michaela J Higgins
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 131:915-24. 2012
    ..Simvastatin appears to modulate estrone sulfate concentrations and its potential chemopreventive activity in breast cancer warrants further investigation...
  23. ncbi request reprint Adjuvant hormonal therapy for premenopausal women with breast cancer
    Regina J Brown
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Semin Oncol 33:657-63. 2006
    ..Other research focuses on identification of improved markers for endocrine response or resistance and on the special side effects of endocrine therapy in young women...
  24. pmc Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence
    Hetty E Carraway
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 114:315-25. 2009
    ..This study evaluates the methylation frequency and pattern in HNSN to determine if detection of hypermethylation of one or more genes is associated with an increased recurrence risk in node negative breast cancer...
  25. ncbi request reprint Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines
    Allison Pledgie-Tracy
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1550 Orleans Street, Baltimore, MD 21231, USA
    Mol Cancer Ther 6:1013-21. 2007
    ..These results support testing sulforaphane in vivo and warrant future studies examining the clinical potential of sulforaphane in human breast cancer...
  26. pmc Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells
    Qingsong Zhu
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Amino Acids 42:887-98. 2012
    ..These data indicate that the pharmacologic inhibition of LSD1 can effectively alter gene expression and that this therapeutic strategy has potential...
  27. pmc Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling
    Yuan Yao
    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Carcinogenesis 31:382-7. 2010
    ..These results suggest that inhibition of SIRT1 deacetylase activity by either pharmacological inhibitors or genetic depletion impairs ERalpha-mediated signaling pathways...
  28. pmc Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells
    Yi Huang
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 4:1006-13. 2005
    ..Understanding the mechanism of p53-mediated cellular responses to polyamine analogue may help to improve the therapeutic efficacy of polyamine analogues in human breast cancer...
  29. ncbi request reprint Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
    Qun Zhou
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB Room 409, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 6:64-9. 2007
    ..Our findings suggest that HDAC inhibitors could restore expression of the silenced ER gene by reorganizing the heterochromatin-associated proteins without alteration in promoter DNA hypermethylation...
  30. pmc Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
    ..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
  31. pmc Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole
    Tatiana M Prowell
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Prev Res (Phila) 4:1993-2001. 2011
    ....
  32. ncbi request reprint Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability
    Judith C Keen
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Biol Chem 280:29519-24. 2005
    ..These data suggest a novel pathway controlling ER expression resulting from the activation of PP2A, potentially providing a novel therapeutic target...
  33. pmc Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells
    Qun Zhou
    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA
    Proteomics 10:1029-39. 2010
    ..Knowledge of the full repertoire of acetylated proteins will provide a foundation for further defining the functions of HDACs in cancer cells...
  34. pmc Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer
    Roisin M Connolly
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 189, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 127:153-62. 2011
    ..However, these unexpected pharmacokinetic findings support further investigation of mechanisms underlying docetaxel elimination pathways...
  35. ncbi request reprint A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 9:5922-8. 2003
    ..This study evaluated the activity of the first-generation analog DENSpm in women with metastatic breast cancer...
  36. pmc The silent estrogen receptor--can we make it speak?
    Madhavi Billam
    The Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, 1650 Orleans St, Baltimore, MD 21231, USA
    Cancer Biol Ther 8:485-96. 2009
    ..Here we will focus especially on silencing the expression of ERα as one such endocrine-resistance mechanism and how it might be exploited clinically...
  37. pmc Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 121:111-20. 2010
    ..In conclusion, concurrent administration of trastuzumab with PLD-docetaxel was not associated with higher risk of cardiac toxicity compared with PLD-docetaxel alone, but led to excessive hand-foot syndrome...
  38. ncbi request reprint New findings about endocrine therapy for breast cancer
    Nancy E Davidson
    Johns Hopkins University, Schools of Medicine and Public Health, Baltimore, MD, USA
    Breast 12:368-72. 2003
    ..Ongoing research is focused on choice of endocrine approach, duration and sequencing of endocrine treatment, identification of better predictive markers for hormone response, and assessment of long-term risks and benefits...
  39. doi request reprint Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer
    Richard C Zellars
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, 401 N Broadway, Suite 1440, Baltimore, MD 21231, USA
    J Clin Oncol 27:2816-22. 2009
    ..We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC)...
  40. pmc Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases
    Julie M Wu
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:1938-46. 2008
    ..A comprehensive comparison of biomarker expression between patients' primary breast carcinoma (PBC) and their metastatic breast carcinomas (MBC) has not been done...
  41. ncbi request reprint A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine
    Judith Clancy Keen
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 81:177-86. 2003
    ..These data suggest that Scriptaid or related HDAC inhibitors are candidates for further study in breast cancer...
  42. ncbi request reprint Trastuzumab in breast cancer
    Leisha A Emens
    Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine Baltimore, Maryland 21231 1000, USA
    Oncology (Williston Park) 18:1117-28; discussion 1131-2, 1137-8. 2004
    ..Here we review the clinical development of this novel agent, emphasizing the potential for therapeutic synergy when trastuzumab is combined with both standard chemotherapy and innovative molecularly targeted and biologic agents...
  43. pmc The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway
    Kideok Jin
    Breast Cancer Program, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Proc Natl Acad Sci U S A 109:2736-41. 2012
    ..These studies suggest that HOXB7 acts as a key regulator, orchestrating a major group of target molecules in the oncogenic hierarchy. Functional antagonism of HOXB7 could circumvent tamoxifen resistance...
  44. ncbi request reprint What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?
    Michaela J Higgins
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Curr Oncol Rep 11:45-50. 2009
    ..This review focuses on new data on how to incorporate OS/OA into the rational treatment of this challenging patient population...
  45. ncbi request reprint Adjuvant hormonal therapy for premenopausal women with breast cancer
    Leisha A Emens
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 9:486S-94S. 2003
    ....
  46. ncbi request reprint Anticancer activities of novel chalcone and bis-chalcone derivatives
    Aneta Modzelewska
    Division of Chemical Therapeutics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Bioorg Med Chem 14:3491-5. 2006
    ..Furthermore, bis-chalcone 8 exhibited a more potent inhibition of colon cancer cells expressing wild-type p53 than of an isogenic cell line that was p53-null...
  47. ncbi request reprint Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1, N11-diethylnorspermine
    Edward Gabrielson
    Department of Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Cancer Chemother Pharmacol 54:122-6. 2004
    ..Therefore, to estimate the response of breast cancers to DENSpm, we measured induction of SSAT in breast cancer explants treated in vitro with this polyamine analogue...
  48. ncbi request reprint A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer
    Leisha A Emens
    Johns Hopkins Oncology Center, Baltimore, MD, USA
    Breast Cancer Res Treat 76:145-56. 2002
    ..Our aims were to determine the maximum tolerated dose (MTD) of 5-FU in the dose-dense regimen and to determine the impact of dose-dense chemotherapy on HDC/PBSCT...
  49. doi request reprint Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium
    Igal Madar
    Russell H Morgan Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Nucl Med 50:774-80. 2009
    ..Here, we have characterized the ability of the novel PET voltage sensor (18)F-fluorobenzyl triphenyl phosphonium ((18)F-FBnTP) to quantify the time-dependent apoptotic action of the taxanes paclitaxel and docetaxel in vitro and in vivo...
  50. doi request reprint Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline
    Kala Visvanathan
    John Hopkins Medical Institution, Baltimore, MD, USA
    J Clin Oncol 31:2942-62. 2013
    ..To update the 2009 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction...
  51. pmc Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer
    Aditya Bardia
    Breast Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building 1, Room 144, 1650 Orleans Street, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 131:907-14. 2012
    ..Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD...
  52. ncbi request reprint Aromatase inhibitors as adjuvant therapy in breast cancer
    Kala Visvanathan
    Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Oncology (Williston Park) 17:335-42, 347; discussion 347-50, 354. 2003
    ..Ongoing trials are assessing the potential role of aromatase inhibitors in the adjuvant, neoadjuvant, and preventive settings...
  53. ncbi request reprint Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Oncologist 7:239-45. 2002
    ..PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions...
  54. ncbi request reprint The follow-up of breast cancer
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University, Baltimore, MD, USA
    Semin Oncol 30:338-48. 2003
    ..Finally, we present an evidence-based approach to breast cancer surveillance after therapy that is consistent with several clinical practice guidelines, maximizing outcome and minimizing cost...
  55. ncbi request reprint Case records of the Massachusetts General Hospital. Case 35-2005. A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node
    Nancy E Davidson
    Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 353:2177-85. 2005
  56. ncbi request reprint Estrogen receptor status, cell cycling and paclitaxel: looking for a "hormone"-ious explanation
    Ben Ho Park
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 3:468-9. 2004
  57. ncbi request reprint Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Breast Cancer 6:334-9. 2005
    ..The purpose of this multicenter phase II trial was to evaluate the clinical activity of topotecan as first-line chemotherapy in patients with metastatic breast cancer and previous exposure to adjuvant doxorubicin...
  58. pmc Integrated proteomic and metabolic analysis of breast cancer progression
    Patrick G Shaw
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    PLoS ONE 8:e76220. 2013
    ..This analysis of metabolic dysfunction in cancer progression integrated with global protein expression and subcellular localization is a novel and useful technique for determining organelle-specific roles of proteins in disease. ..
  59. ncbi request reprint Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid
    Mary Jo Fackler
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore Maryland, USA
    Clin Cancer Res 12:3306-10. 2006
    ..We hypothesized that quantitative analysis of methylated genes will provide enhanced detection of cancer cells present in cytologic specimens...
  60. ncbi request reprint Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast
    Brian S Cornblatt
    Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
    Carcinogenesis 28:1485-90. 2007
    ..These findings provide a strong rationale for evaluating the protective effects of a broccoli sprout preparation in clinical trials of women at risk for breast cancer...
  61. pmc A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells
    Yi Huang
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 9:2769-77. 2003
    ....
  62. ncbi request reprint Molecular mechanisms of polyamine analogs in cancer cells
    Yi Huang
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Anticancer Drugs 16:229-41. 2005
    ..The development and use of these analogs have provided valuable information for understanding the molecular mechanisms of targeting the polyamine pathway as a means of cancer therapy...
  63. ncbi request reprint Aromatase inhibitors for breast cancer
    Susanne Briest
    Department of Gynecology and Obstetrics, University of Leipzig, Leipzig, Germany
    Rev Endocr Metab Disord 8:215-28. 2007
    ..Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed...
  64. doi request reprint Martin D. Abeloff, MD
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    J Clin Oncol 26:1573-4. 2008
  65. ncbi request reprint Exercise manages fatigue during breast cancer treatment: a randomized controlled trial
    Victoria Mock
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, USA
    Psychooncology 14:464-77. 2005
    ..Adherence to a home-based moderate-intensity walking exercise program may effectively mitigate the high levels of fatigue prevalent during cancer treatment...
  66. pmc Gene expression profiling of breast cancer
    Ting Bao
    The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Adv Surg 42:249-60. 2008
    ..It is expected that availability of these types of analyses will only increase in the future. It will be imperative that such assays be well validated and have implications for how to modify care for the individual patient...
  67. ncbi request reprint Estrogen carcinogenesis in breast cancer
    James D Yager
    Bloomberg School of Public Health, Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205, USA
    N Engl J Med 354:270-82. 2006
  68. ncbi request reprint Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer
    Agoston T Agoston
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231 1000, USA
    J Biol Chem 280:18302-10. 2005
    ..The regulation of DNMT1 destruction via this domain may be dysfunctional in cancer cells leading to subsequent cytosine hypermethylation in the genome...
  69. ncbi request reprint Silencing estrogen receptor alpha in breast cancer cells
    Qun Zhou
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 5:848-9. 2006
  70. ncbi request reprint The importance of cytologic intrarater and interrater reproducibility: the case of ductal lavage
    Kala Visvanathan
    Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
    Cancer Epidemiol Biomarkers Prev 15:2553-6. 2006
    ..27 +/- 0.09. Fair to moderate intrarater and interrater agreement of DL cytology was observed. Low intrarater and interrater cytologic consistency may compromise the interpretation of clinical studies of DL...
  71. ncbi request reprint Of Snail, mice, and women
    Nancy E Davidson
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Cell 8:173-4. 2005
    ..The identification of a molecular pathway involved in mammary tumor recurrence in a mouse model offers both opportunity and challenge to confirm, extend, and exploit these findings in the clinic...
  72. ncbi request reprint Tracking 35 years of progress against breast cancer
    Nancy E Davidson
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, USA
    Oncology (Williston Park) 22:593-5. 2008
  73. ncbi request reprint Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry
    Jinong Li
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Clin Chem 51:2229-35. 2005
    ....
  74. ncbi request reprint Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications
    Michael A Jacobs
    The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Technol Cancer Res Treat 3:543-50. 2004
    ..A combination of MR, MRSI, and 23Na sodium MR parameters may be examined in a single MR imaging examination, potentially resulting in improved specificity for radiologic evaluation of malignancy...
  75. ncbi request reprint Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents
    Srinivas K Kumar
    Division of Experimental Therapeutics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Med Chem 46:2813-5. 2003
    ..The results show the boronic-chalcones are more toxic to breast cancer cells compared to normal breast cells than other known chalcones...
  76. ncbi request reprint The biology of breast carcinoma
    Judith Clancy Keen
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 97:825-33. 2003
    ..Studies of the biology of these and other genes that contribute to the development and progression of breast carcinoma have had and will continue to have great impact on all aspects of disease management...
  77. ncbi request reprint A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  78. pmc Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    Lori J Goldstein
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:4092-9. 2008
    ..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer...
  79. pmc Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Lori J Goldstein
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:4063-71. 2008
    ..Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features...
  80. doi request reprint Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
    Sunil S Badve
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:2473-81. 2008
    ....
  81. ncbi request reprint Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    Patrick C Roche
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Natl Cancer Inst 94:855-7. 2002
    ..The concordance for central HercepTest and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831...
  82. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  83. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  84. ncbi request reprint Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  85. ncbi request reprint Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer
    Nancy E Davidson
    J Natl Cancer Inst 97:159-61. 2005
  86. ncbi request reprint Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196
    Joseph A Sparano
    Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10461, USA
    J Clin Oncol 22:4683-90. 2004
    ..To determine whether a matrix metalloproteinase inhibitor improves progression-free survival (PFS) in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy...
  87. ncbi request reprint Breast cancer consensus meetings: vive la difference?
    Nancy E Davidson
    J Clin Oncol 20:1719-20. 2002
  88. ncbi request reprint Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
    Edith A Perez
    North Central Cancer Treatment Group, Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 22:3700-4. 2004
    ....
  89. ncbi request reprint Déjà vu for breast cancer two?
    Vered Stearns
    J Natl Cancer Inst 96:497-9. 2004
  90. ncbi request reprint Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines
    Lan Yan
    Sidney Kimmel Comprehensive Cancer at Johns Hopkins University Medical School, Baltimore, Maryland USA
    Cancer Biol Ther 2:552-6. 2003
    ..Our results suggest that specific inhibition of DNMT1 expression alone is sufficient to re-express ERa in human breast cancer cell lines...
  91. ncbi request reprint Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....
  92. ncbi request reprint A "bone" fide predictor of metastasis? Predicting breast cancer metastasis to bone
    Scott L Kominsky
    J Clin Oncol 24:2227-9. 2006
  93. ncbi request reprint Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Antonio C Wolff
    J Clin Oncol 24:2392-4; author reply 2394-5. 2006
  94. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
    ..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...
  95. doi request reprint Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  96. pmc Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  97. ncbi request reprint Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  98. ncbi request reprint Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death
    Meihua Sui
    Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Res 67:5337-44. 2007
    ..The results obtained from this study provide useful information for understanding ER-mediated resistance to paclitaxel and possibly other antineoplastic agents...
  99. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  100. ncbi request reprint A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group
    Robert W Carlson
    Stanford University, Stanford, California 94305 5826, USA
    Cancer Invest 24:677-81. 2006
    ..To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer...
  101. ncbi request reprint Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer
    Antonio C Wolff
    J Clin Oncol 24:4949-51. 2006

Research Grants3

  1. DNA METHYLATION AS A DETERMINANT OF BREAST CANCER
    Nancy Davidson; Fiscal Year: 2002
    ..Taken together these studies should provide new insights into the biology of hormone resistance and possible novel therapeutic targets. ..
  2. SPORE IN BREAST CANCER
    Nancy Davidson; Fiscal Year: 2007
    ....